2013
The CD226/CD155 Interaction Regulates the Proinflammatory (Th1/Th17)/Anti-Inflammatory (Th2) Balance in Humans
Lozano E, Joller N, Cao Y, Kuchroo VK, Hafler DA. The CD226/CD155 Interaction Regulates the Proinflammatory (Th1/Th17)/Anti-Inflammatory (Th2) Balance in Humans. The Journal Of Immunology 2013, 191: 3673-3680. PMID: 23980210, PMCID: PMC3819731, DOI: 10.4049/jimmunol.1300945.Peer-Reviewed Original ResearchConceptsNaive T cellsT cellsInflammatory balanceIL-13IL-17-producing cellsRole of CD226IL-17 productionIL-17 secretionHuman autoimmune diseasesIFN-γ productionIL-13 secretionIFN-γ expressionProduction of IFNSTAT-6 phosphorylationT cell activationHuman T cellsLigand CD155Th17 cellsIL-17Autoimmune diseasesIL-4T-betTh1 differentiationTh17 conditionsTherapeutic approaches
2008
CTLA4Ig treatment in patients with multiple sclerosis
Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, Egorova S, Guttmann CR, Rusche JR, Khoury SJ. CTLA4Ig treatment in patients with multiple sclerosis. Neurology 2008, 71: 917-924. PMID: 18794494, DOI: 10.1212/01.wnl.0000325915.00112.61.Peer-Reviewed Original ResearchConceptsMultiple sclerosisCostimulatory pathwayPhase 1 dose-escalation studyT cell-mediated autoimmune diseaseCell-mediated autoimmune diseaseRelapsing-remitting multiple sclerosisT-cell costimulatory pathwaysCostimulatory molecule interactionsMonths of infusionDose-escalation studyInterferon-gamma productionT cell activationOriginal therapeutic approachAdverse eventsImmunologic assessmentImmunologic effectsCTLA4Ig treatmentChronic inflammationAutoimmune diseasesInflammatory processT cellsImmune responseTherapeutic approachesCTLA4IgExtension study
2007
New Therapeutic Approaches for Multiple Sclerosis
De Jager PL, Hafler DA. New Therapeutic Approaches for Multiple Sclerosis. Annual Review Of Medicine 2007, 58: 417-432. PMID: 17217332, DOI: 10.1146/annurev.med.58.071105.111552.Peer-Reviewed Original ResearchConceptsCentral nervous systemMultiple sclerosisNeurodegenerative componentImmunology of MSLarge unmet clinical needSubset of patientsUnderlying pathophysiologic processEffective immunomodulatory treatmentsEntry of lymphocytesNew therapeutic approachesUnmet clinical needCategories of diseaseImmunomodulatory treatmentInflammatory componentCurrent therapiesImmune homeostasisImmune responseIndividual patientsPathophysiologic processesTherapeutic approachesTreatment approachesNervous systemPatientsHealthy profileClinical need
1991
Immunotherapy in autoimmune diseases
Miller A, Hafler D, Weiner H. Immunotherapy in autoimmune diseases. Current Opinion In Immunology 1991, 3: 936-940. PMID: 1793539, DOI: 10.1016/s0952-7915(05)80017-2.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunomodulatory therapeutic approachesHuman autoimmune diseasesMajor histocompatibility complex moleculesReceptor gene productsT cell recognitionHistocompatibility complex moleculesImmune interventionImmunological toleranceTherapeutic approachesAnimal modelsDiseaseImmunotherapyTrimolecular complexMolecular basis